Q-omics provides the consensus-scored CCDC74A profile across patient tissues and cancer cell-line models. CCDC74A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CCDC74A is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, CCDC74A RNA expression shows 16,326 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where CCDC74A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC74A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC74A survival associations across molecular data types. CCDC74A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC74A RNA expression–survival associations across cancer types. High CCDC74A expression shows unfavorable associations in UVM, KICH, KIRC and BLCA, but favorable associations in BRCA and MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for CCDC74A RNA expression.
This table summarizes CCDC74A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC74A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC74A shows lower tumor expression in KICH and higher tumor expression in KIRC, KIRP, COAD, THCA and BRCA. The KIRC box plot shows higher CCDC74A RNA expression in tumor versus normal tissue (log2 FC = +1.406, t-test p < 0.001).
This table shows molecular features associated with CCDC74A in patient tissues and cancer cell lines. In patient samples, CCDC74A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC74A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
